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Abstract 
 
Acute treatment with subanaesthetic ketamine, a non-competitive NMDA receptor 
antagonist, is widely utilized as a translational model for schizophrenia. However, how acute 
NMDA receptor blockade impacts on brain functioning at a systems level, to elicit 
translationally relevant symptomatology and behavioural deficits, has not yet been 
determined. Here, for the first time, we apply established and recently validated topological 
measures from network science to brain imaging data gained from ketamine treated mice to 
elucidate how acute NMDA receptor blockade impacts on the properties of functional brain 
networks. We show that the effects of acute ketamine treatment on the global properties of 
these networks are divergent from those widely reported in schizophrenia. Where acute 
NMDA receptor blockade promotes hyperconnectivity in functional brain networks, 
pronounced dysconnectivity is found in schizophrenia. We also show that acute ketamine 
treatment increases the connectivity and importance of prefrontal and thalamic brain 
regions in brain networks, a finding also divergent to alterations seen in schizophrenia. In 
addition, we characterise how ketamine impacts on bipartite functional interactions 
between neural subsystems. A key feature includes the enhancement of PFC-
neuromodulatory subsystem connectivity in ketamine treated animals, a finding consistent 
with the known effects of ketamine on PFC neurotransmitter levels. Overall, our data 
suggest that, at a systems level, acute ketamine-induced alterations in brain network 
connectivity do not parallel those seen in chronic schizophrenia. Hence, the mechanisms 
through which acute ketamine treatment induces translationally relevant symptomatology 
may differ from those in chronic schizophrenia. Future effort should therefore be dedicated 
to resolving the conflicting observations between this putative translational model and 
schizophrenia. 
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 1. Introduction 
 
Schizophrenia is a common, chronic psychiatric disorder characterised by positive symptoms 
(e.g. hallucinations), negative symptoms (e.g. blunted affect) and cognitive deficits (e.g. 
executive functioning and memory). The disorder involves dysfunction in a number of brain 
regions including the prefrontal and temporal cortices, the hippocampus and thalamic 
regions. Recent data from functional brain imaging studies in schizophrenia has advanced 
our understanding of how functional interactions between distinct neural subsystems, such 
as the prefrontal cortex (PFC) and hippocampus ([HP], Meyer-Lindenberg et al., 2005; 
Benetti et al., 2009) and between other discrete cortical regions (Kim et al., 2005) are 
disrupted in the disorder.  However, given that these studies often involve a priori selection 
of the functional interaction of interest, the data may over-emphasise the relative 
importance of these particular interactions while missing others that are biologically 
important. Therefore, there has been much interest in taking the alternative approach of 
characterising disrupted functional interactions between brain regions in the context of 
complex brain networks, which may provide added insight to those interactions disrupted in 
schizophrenia (Lynall et al., 2010; Micheloyannis et al., 2006; Bassett et al., 2008; Liu et al., 
2008). More recently these approaches have also been applied to further understand how 
risk factors for psychiatric disorder impact on structural brain networks (Li et al., 2012) and 
their application to preclinical brain imaging data with translational relevance to the disorder 
has started to emerge (Bifone et al., 2010; Dawson et al., 2012a). 
 
There is compelling evidence to support a role for altered glutamate system functioning, and 
N-methyl-D-aspartic acid (NMDA) receptor hypofunction in particular, in schizophrenia. For 
example, recent in vivo 1H magnetic resonance spectroscopy (1H-MRS) data support altered 
glutamate and glutamine levels in the brains of schizophrenia patients (de la Fuente-
Sandoval et al., 2011; Marsman et al., 2013; Natsubori et al., 2013). Furthermore, both acute 
and repeated exposure to NMDA receptor antagonists can induce schizophrenia-like 
symptoms in humans (Cosgrove et al., 1991; Krystal et al., 1994) and acute treatment with 
the NMDA receptor antagonist ketamine exacerbates the symptoms of schizophrenia 
patients (Lahti et al., 2001; Malhotra et al., 1997). Due to these observations acute, 
subanaesthetic ketamine treatment has become one of the most widely utilised 
pharmacological manipulations in both humans (Krystal et al., 1994; Morgan et al., 2004; 
D’Souza et al., 2012) and animals (Nikiforuk et al., 2010; Pitsikas et al., 2008; Roberts et al., 
2010; Skoblenick and Everling, 2012) to model translationally relevant behavioural deficits 
relevant to schizophrenia. For example, in rodents the subanaesthetic dose of ketamine 
used in this study (30mg.kg-1) has been shown to induce deficits in the startle response (as 
measured by pre-pulse inhibition), hyperlocomotion and deficits in working memory that 
have translational relevance to schizophrenia (Galci et al., 2008; Irifune et al., 1991; Kos et 
al., 2006; Miyamoto et al., 2000; Verma and Moghaddom et al., 1996; Yang et al., 2010). In 
addition many studies, in both humans (Langsjo et al., 2004; Vollenweider et al., 1997a; 
1997b) and animals (Chih-Liang et al., 2011; Dawson et al., 2013) have been dedicated to 
elucidating the impact of acute, subanaesthetic ketamine treatment on regional brain 
functioning, with PFC hypermetabolism (hyperfrontality) most consistently reported. The 
paradox of this ketamine-induced hyperfrontality given the hypofrontality characteristic of 
long-term schizophrenia (Hill et al., 2004) has not been resolved. Surprisingly, despite the 
widespread use of ketamine treatment as a translational model there is a relative paucity of 
data on how acute ketamine treatment impacts on the functional interactions between 
brain regions and the neural subsystems known to be dysfunctional in schizophrenia. 
Indeed, only recently have efforts begun to elucidate how acute, subanaesthetic doses of 
ketamine impact on functional connectivity between select brain regions (Niesters et al., 
2012; Dawson et al., 2013). Furthermore, to our knowledge, no study has considered the 
impact of subanaesthetic ketamine treatment on functional brain network structure or on 
functional interactions between neural subsytems within the context of complex brain 
networks. Here, for the first time, we apply topological measures based on the algorithms of 
network science to functional 2-deoxyglucose (2-DG) autoradiographic brain imaging data to 
quantitatively define how acute ketamine treatment impacts on functional brain network 
connectivity on a global, regional and neural subsystem scale. Given that recent studies have 
begun to quantify brain network alterations in schizophrenia, the recent transition of these 
algorithms to preclinical brain imaging data, and the great interest in the application of 
subanaesthetic ketamine treatment as a translational model for the disorder, it is 
particularly timely to characterise altered brain network structure in this model. Here, we 
test the hypothesis that acute NMDA receptor hypofunction models the systems level 
alterations seen in functional brain networks in schizophrenia and gain new, quantitative 
insight into the true nature of disrupted brain functioning in this translational model through 
the application of this analytical approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Materials and Methods 
All experiments were completed using male C57BL/6J mice (aged 8-9 weeks) group housed 
(5-6 animals per cage) under standard conditions (21oC, 45-65% humidity, 12-h dark/light 
cycle [lights on 0600h]). All experimental manipulations were carried out at least 1 week 
after entry into the facility and all experiments were carried out under the Animals (Scientific 
Procedures) Act 1986. Access to food was restricted for 4 to 5 hours prior to the semi-
quantitative 14C-2-deoxyglucose imaging protocol to obviate the potential influence of 
ketamine treatment on plasma glucose levels. 
2.1 Semi-quantitative 14C-2-deoxyglucose Autoradiographic Imaging 
Measurement of local cerebral glucose utilisation (LCGU) was initiated 1 minute after the 
treatment of mice with 30mg.kg-1 ketamine (Sigma-Aldrich, UK; in 2ml.kg-1 saline, 
interperitoneally [i.p.], n = 9) or physiological saline (1.25 mls.kg-1 , i.p., n = 9) in accordance 
with previously published protocols (Dawson et al., 2011; 2013). Mice were injected with 
4.625 MBq.kg-1 of [14C]-2-deoxyglucose (Perkin-Elmer, UK) at a steady rate over a 10 second 
period before being returned to their home cage. At exactly 45 minutes after isotope 
injection animals were decapitated and a terminal blood sample was collected, by torso 
inversion, in heparinised weigh boats. The timing of this imaging protocol ensures that the 
alterations in brain functioning detected align with the maximal behavioural effects of this 
dose of ketamine (Miyamoto et al., 2000; Yang et al., 2010). The brain was rapidly dissected 
out intact then frozen in isopentane (-40oC) and stored at -80oC until sectioning. Blood 
samples were centrifuged to separate the plasma and aliquots were removed for the 
determination of plasma glucose (10µl) and 14C (20µl) concentrations by semi-automated 
glucose oxidase assay (Beckman Glucose Analyser) and liquid scintillation analysis (Packard), 
respectively. 
Frozen brains were sectioned (20μm) in the coronal plane in a cryostat (-20oC). A series of 
three consecutive sections were retained from every 60μm, thaw mounted onto slide covers 
and rapidly dried on a hot plate (70oC). Autoradiograms were generated by apposing these 
sections, together with precalibrated 14C-standards (40-1069 nCi/g tissue equivalents: 
Amersham International, UK) to X-ray film (Kodak, SB-5) for 5 days. Autoradiographic images 
were analysed by a computer-based image analysis system (MCID/M5+). The local isotope 
concentration for each brain region of interest (RoI) was derived from the optical density 
(O.D.) of autoradiographic images relative to that of the coexposed 14C standards. 
Measurements were taken from 66 anatomically distinct brain regions defined with 
reference to a stereotaxic mouse brain atlas (Paxinos and Franklin, 2001). The rate of 
metabolism, LCGU, in each RoI was determined as the ratio of 14C present in that region 
relative to the average 14C concentration in the whole brain of the same animal, and from 
hereon in will be referred to as the 14C-2-DG uptake ratio. Whole brain average 14C levels 
were determined from the average 14C concentration across all sections in which a RoI was 
measured. Ketamine induced alterations in overt LCGU were analysed using Student’s t-test 
and significance was set at p<0.05, and anatomically discrete brain regions were assumed to 
represent independent variables (as previously discussed in McCulloch et al., 1982). 
2.2 Inter-regional correlations and functional brain networks 
The inter-regional Pearson’s correlation coefficient was used as the metric of the functional 
association between brain regions generated from the 14C-2-DG uptake ratios for each RoI 
across all animals within the same experimental group (i.e. either control or ketamine-
treated). These correlations were Fisher z-transformed to give the correlation data a more 
normal distribution. This resulted in a pair of {66 x 66} correlation matrices, each within-
group matrix representing the specific association strength between each of the 2,145 
possible pairs of regions. From each correlation matrix (R) we derived a binary adjacency 
matrix (A) where the functional connection between two regions (ai,j element) was zero if 
the Pearson’s correlation coefficient was lower than the defined threshold (p|i,j|<T) and 
unity if the coefficient was greater or equal to the defined threshold (p|i,j|≥T). The 
adjacency matrix can also be represented as an undirected graph G, where a line or edge 
represents the functional interaction between two brain regions (nodes) if the correlation 
coefficient exceeds the defined threshold value.  
2.3 Network Analysis 
Network architecture was characterised at the global, divisional and regional scales. Global 
network architecture was quantified in terms of the mean degree (<k>), average pathlength 
(Lp) and mean clustering co-efficient (Cp) of the whole brain network, as previously described 
in Dawson et al., 2012a and outlined in Section 2.4 below. Alterations in divisional 
architecture were determined in terms of altered functional clustering, identified in the 
brain networks through application of the generalized singular value decomposition (GSVD) 
algorithm (Dawson et al., 2012a;  Xiao et al., 2011), that provides a data driven approach to 
identifying clustering difference between the two experimental matrices. Regional 
properties were defined in terms of degree (ki), betweeness (Bc) and closeness (Cc) 
centrality. Global and regional metrics were determined on the binary adjacency matrices 
generated over a range of correlation thresholds (Pearson’s r, T = 0.3 to 0.4, Fisher’s z, T = 
0.310 to 0.424) that were selected on the basis that the maximum threshold utilised yielded 
fully connected networks in each treatment group and was similar to that utilised in previous 
reports (Dawson et al., 2012; Liu et al., 2008; Micheloyannis et al., 2006). 
 2.4 Global Network Architecture 
Here we provide brief, formal definitions of the global network metrics determined in this 
study.  
The degree of a node (k) is simply the number of edges that connect that node to the 
network, so highly connected nodes have a high degree. The mean degree (<k>, equation 
[1]) is the average number of edges across all nodes. A sparse network therefore has a low 
mean degree.  
      (1) 
The minimum path length between two nodes in a graph (Li,j) is the smallest number of 
edges that must be traversed to make a connection between them. If two nodes are 
immediate neighbours, directly connected by a single edge, then Li,j = 1. The average path 
length (Lp, equation [2]), or average Li,j across all possible pairs, is the average number of 
steps along the shortest paths across the network. This provides a measure of global 
network efficiency, where networks with a low average path length are more efficient. 
    (2) 
The clustering coefficient of node i (Ci) is the ratio of the number of edges between 
neighbours of node i relative to the maximum possible number of connections between 
them. It provides an indication of how well connected the neighbourhood of a node is. The 
mean clustering coefficient (Cp, equation [3]) is the average clustering coefficient of all of the 
nodes in the network, which provides a measure of the local density or cliquishness of the 
network. A high mean clustering coefficient suggests high clustering and so efficient local 
information transfer.  
     (3) 
The significance of ketamine-induced alterations in the global properties of 2-DG functional 
brain networks was determined by comparison of the real difference in each measure to 
that of networks generated from 1,000 to 5,000 random permutations of the raw 2-DG data 
at each correlation threshold (11,000 to 55,000 random permutations in total). Significance 
was set at p<0.05 and was determined from the average p-value across the entire 
correlation threshold range analysed. 
2.5 Regional centrality and Hub region identification 
In this study we consider node centrality as determined by degree (ki), betweeness (Bc) and 
closeness (Cc). Degree centrality (ki) simply measures the number of nodal connections. 
Betweeness centrality (Bc, equation [4]) is based upon how many short paths go through a 
given node and for the ith node in a graph (G) is defined by:  
   (4) 
Here σst denotes the number of shortest paths from node s to node t, and σst(i) denotes the 
number of these that involve node i.  
Closeness centrality (Cc, equation 5) is based upon the mean geodesic distance of a node to 
all other reachable nodes in the network, given by:  
   (5) 
Here dG(i,t) denotes the geodesic between nodes i and t.  
A brain region that is considered to be an important hub region in the network has a high 
degree, betweenness or closeness centrality. In this study a brain region was defined as a 
hub in the brain networks of ketamine-treated or control (saline-treated) animals if, for any 
centrality measure, the regional centrality measure in the real network relative to that of 
calibrated random Erdös-Rényi graphs (1,000 random graphs at each correlation threshold, 
11,000 random graphs in total), was z>1.96. The z-score for each centrality measure was 
calculated as illustrated in equation 6 for the case of betweenness centrality (Bc) 
           (6) 
The significance of ketamine-induced alterations in regional centrality was determined by 
comparison of the z-score difference in regional centrality in the real brain networks with 
that in networks generated from 11,000 random permutations of the raw 2-DG data (1,000 
random permutations at each correlation threshold). Significance was set at p<0.05 with 
post-hoc Bonferroni correction applied to adjust for multiple comparisons on the basis of 
comparing 66 RoI.  
2.6 Divisional architecture; bipartite neural subsystem interactions 
Differences in the divisional architecture of the functional brain networks between 
experimental groups was characterised through the application of a recently developed and 
validated algorithm for cluster identification based upon generalized singular value 
decomposition (GSVD). The functionality of this algorithm has previously been proposed, 
justified and validated through its application to both synthetic and real biological data sets 
(Xiao et al., 2011), and has previously been applied to preclinical brain imaging data (Dawson 
et al., 2012a).  In the context of this study the aim of applying this algorithm to the data was 
to quantitatively define the functional interactions between two defined neural subsystems 
(bipartite interactions) that are present in one of the experimental groups but not the other. 
The ability of the algorithm to elucidate mutually exclusive clusters in two matrices has 
previously been validated through its application to synthetic data sets (Xiao et al., 2011).  
In essence this algorithm allows the re-ordering of two square, symmetric, real-valued 
matrices A and B with the aim of discovering a new node (brain region) ordering that reveals 
clusters of nodes that exhibiting strong functional connectivity (mutual weights) in one 
network but not the other. In the case of our data, matrix A and matrix B are comprised of 
the real-value inter-regional correlation coefficients (Pearson’s coefficient Fisher 
transformed) for the control and ketamine treatment group’s respectively. These matrices 
are identical to those used for the generation of the binary adjacency matrices used to 
characterise the global and regional characteristics of the functional brain networks in these 
experimental groups. Once the matrices have been reordered through this iterative 
algorithm we assessed whether the variance of the node set for a given pair of defined 
neural subsystems (defined neural subsystems are shown in Figure 4) in the reordered 
matrix was significantly lower than expected by chance. To determine this the variance of 
the nodes for the two neural subsystems of interest in the real GSVD reordered networks 
was compared with that of a set of nodes equal in size to that of the defined neural 
subsystem in matrices derived from 10,000 random permutations of the raw data. The p-
values gained from this permutation analysis were corrected by post-hoc Bonferroni-Holm 
correction to adjust for multiple comparisons (110 neural subsystem comparisons made in 
the control and ketamine treated data sets [55 in each experimental group]). Significance 
was set at p<0.05. 
 
 
 
 
 
 
 
 
 
3. Results 
3.1 Ketamine-induced alterations in overt cerebral metabolism 
 
Acute ketamine treatment produced both significant increases and decreases in cerebral 
metabolism on a region-dependent basis, consistent with previous reports (Dawson et al., 
2013; Duncan et al., 1999). Significant overt alterations in cerebral metabolism were 
identified in 32 of the 66 regions analyzed (Supplementary Table S1[A-D]); Select regions 
shown in Figure 1). In particular, acute ketamine treatment induced hyperfrontality, an 
increased rate of cerebral metabolism in subfields of the PFC, an effect that was evident in 
all subfields of the prelimbic cortex (anterior prelimbic [PrL] and medial prelimbic (layers 1, 2 
and 3 [mPrL1, mPrL2, mPrL3]). In addition, significant hypermetabolism was found in the 
entorhinal cortex (EC) and subfields of the hippocampus (molecular layer [ML] and 
subiculum [Sub]), the nucleus accumbens core (NacC), substantia nigra pars compacta (SNC) 
and the mamillary body (MB). By contrast, acute ketamine treatment induced significant 
thalamic hypometabolism (anteroventral [AVthal], mediodorsal [MDthal], ventrolateral 
[VLthal] and dorsal reticular [dRT]), along with hypometabolism in the raphé (dorsal [DR], 
median [MR] and paramedian [PMR]), tegmental (dorsal [DTg] and ventral [VTg]) and 
habenula (medial [mHab] and lateral [lHab]) nuclei. In addition, ketamine-treatment induced 
significant hypometabolism in the locus coeruleus (LC), the diagonal band of broca 
(horizontal [HDB] and vertical [VDB]), medial geniculate (MG), inferior colliculus (IC), the CA3 
subfield of the hippocampus and in the retrosplenial cortex (RSC). 
 
3.2 Ketamine-induced alterations in global functional brain network topology 
 
Acute ketamine treatment resulted in a functional brain network with increased 
connectivity, as evidenced by the significant increase in mean degree (<k>, P = 0.0490), the 
average number of functional connections each brain region (node) has in the network, 
across the entire correlation threshold range (Figure 2[A]). However, while the number of 
connections in the brain network was significantly increased by ketamine treatment this did 
not significantly impact on average path length (Lp, Figure 2[B], P = 0.207), across the 
observed correlation threshold range. A low average path length is indicative of a network 
organised for efficient information transfer on a global scale. The observation that ketamine 
does not alter Lp, thus does not alter the efficiency of information transfer across the 
network, is surprising given the increased number of functional connections (mean degree, 
Figure 2[A]) seen in the brain networks of these animals, but suggests that the efficiency of 
information transfer across the network on a global scale is not modified by acute ketamine 
treatment. By contrast acute ketamine treatment induced a significant increase in the mean 
clustering coefficient (Cp, Figure 2[C], P = 0.0333), a measure of local connectivity or 
cliquishness in the brain network, across the entire correlation threshold range analysed. 
This indicates that acute ketamine treatment induces a topological reorganisation of the 
functional brain network resulting in increased efficiency for localised information transfer. 
When brain networks were considered at the same cost, in essence comparing the global 
properties of the functional brain networks when they have the same number of functional 
connections (by allowing weaker functional connections in control animals to be considered 
as connected) there was no significant difference in the average path length (Lp, Figure 1[D], 
P = 0.0987) or the mean clustering coefficient (Cp, Figure 1[E], P = 0.1448) of the brain 
networks. This suggests that the enhanced efficacy of functional connections between brain 
regions, as indicated by a significantly increased mean degree (<k>), that results from 
ketamine treatment underlies the increased mean clustering coefficient (Cp) seen in the 
brain networks of these animals. 
 
3.3 Ketamine induced alterations in regional functional connectivity 
 
In the functional brain networks of control (vehicle treated) animal’s 4 of the 66 brain 
regions analysed were identified as important hubs by centrality analysis (Figure 3, Table 1) 
including the retrosplenial cortex (RSC), nucleus accumbens shell (NacS), interpeduncular 
nucleus (IP) and mammillary body (MB). In the functional brain network of ketamine treated 
animals an increased number of brain regions (14 out of 66) were identified as important 
hubs. This included two subfields of the prefrontal cortex (lateral orbital [LO], medial 
prelimbic cortex, layer 3 [mPrL3]), 4 thalamic nuclei (anteromedial thalamic nucleus 
[AMthal], mediodorsal thalamus [MDthal], ventromedial thalamus [VMthal] and the 
centrolateral thalamus [CLthal]) and 2 amygdala nuclei (medial amygdala [meA], basolateral 
amygdala [BLA]). There was little overlap in the identity of brain regions identified as 
important hubs in the functional brain network of ketamine treated and control animals, 
with only the nucleus accumbens shell (NacS) being identified as an important hub in the 
functional brain network of both experimental groups. This suggests that the organization of 
the functional brain network is markedly altered by ketamine treatment. Indeed, a 
statistically significant increase in regional centrality was found for 2 PFC subfields (mPrL3, 
LO), 3 thalamic nuclei (MDthal, VMthal, CLthal), 2 amygdala nuclei (MeA, BLA) and the 
medial habenula (mHab, Table 1). Therefore, these brain regions show significantly 
increased connectivity and importance in the brain networks of ketamine treated animals. 
By contrast, ketamine treatment induced a significant reduction in regional centrality for the 
retrosplenial cortex (RSC) and mammillary body (MB), suggesting that these hub brain 
regions in the brain network of control animals were less important and showed significantly 
reduced connectivity in the brain networks of ketamine treated animals (Table 1). 
 
3.4 Ketamine induced alterations in bipartite neural subsystem interactions 
 
GSVD analysis, allowing for the identification of bipartite neural subsystem interactions, 
revealed that in control animals the thalamus was significantly functionally coupled to both 
the hippocampus (P = 0.043) and the neuromodulatory nuclei (P = 0.011, Figure 4). The 
functional interactions between these neural subsytems was not significant in ketamine-
treated animals. Rather, GSVD analysis revealed a significant interaction between the 
neuromodulatory nuclei and the prefrontal cortex (P = 0.043) and other cortical regions 
(cortex subsystem, P = 0.022) in ketamine treated animals that was not significantly present 
in controls. In addition, a significant functional interaction between the thalamus and cortex 
subsystems (P = 0.040) was found in ketamine treated animals that was not present in the 
brain network of control animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Discussion 
 
Through the application of established and recently validated network science algorithms we 
have gained important new insight into how acute NMDA receptor blockade impacts on 
brain functioning at a systems levels. Importantly, ketamine induced alterations in the global 
properties of functional brain networks (supporting enhanced connectivity) do not parallel 
those seen in schizophrenia patients (Micheloyannis et al., 2006; Liu et al., 2008; Lynall et al., 
2010), that overall support widespread functional dysconnectivity in the disorder. In 
particular our data support a ketamine induced enhancement of prefrontal, thalamic and 
amygdala regional functional connectivity, as determined by centrality analysis (Table 1, 
Figure 3). Furthermore, our analysis of ketamine induced alterations in bipartite neural 
subsystem interactions suggests that the connectivity of these, and other, neural subsystems 
is profoundly altered as a result of acute ketamine treatment. 
 
Functional brain networks in chronic schizophrenia characteristically have fewer connections 
(reduced mean degree <k>), a decreased efficiency for global information transfer (increased 
average pathlength, Lp) and decreased local connectivity (decreased mean clustering, Cp 
[Micheloyannis et al., 2006; Liu et al., 2008; Lynall et al., 2010]). By contrast, we have shown 
that acute ketamine treatment results in a functional brain network with increased 
connectivity, as evidenced by an increased number of functional connections (Figure 2(A), 
increased mean degree, <k>), and increased local connectivity (Figure 2(C), increased mean 
clustering coefficient, Cp). While the functional connectivity measure utilised in our study is 
derived from regional metabolic activity across an extended time period, rather than in real 
time as derived in human brain imaging studies, the parallels between the network 
connectivity alterations detected using our approach in mice and that reported in recent 
human brain imaging studies suggests that this is a valid approach. For example, the 
increased functional connectivity found in brain networks of mice treated with ketamine in 
our study parallels the increased functional connectivity found in the brain of healthy 
humans treated with subanaesthetic ketamine (Driesen et al., 2013). These data suggest 
that, at a systems level, the mechanisms through which acute ketamine treatment induces 
schizophrenia-like symptoms may be profoundly divergent from those that contribute to 
these symptoms in the disorder. This suggestion is also consistent with the alterations we 
have identified at the level of regional connectivity, as determined through centrality 
analysis, which supports both enhanced PFC and thalamic functional connectivity. Therefore, 
our data suggest that the disruption of PFC-dependent cognitive processes by subanaestetic 
ketamine treatment (Krystal et al., 2000; Nikiforuk et al., 2010; Moghaddam et al., 1997) 
results not from PFC functional dysconnectivity, but may result from abnormally increased 
PFC functional connectivity, a suggestion consistent with our previous observation that 
ketamine enhances functional connectivity between subfields of the PFC (Dawson et al., 
2013). Decreased PFC functional connectivity is widely reported in schizophrenia (Deserno et 
al., 2012; Honey et al., 2005; Spence et al., 2000; Zhou et al., 2007), although some studies 
have identified regionally selective increases in PFC connectivity in the disorder (Schlsser et 
al., 2003; Klingner et al., 2013). Overall our data suggest that rather than impeding the 
capability of the PFC to receive, integrate and output relevant information to other neural 
subsystems, through PFC dysconnectivity as seen in schizophrenia, acute ketamine 
treatment may decreases the signal-to-noise ratio of information received by the PFC, by the 
promotion of an abnormally increased functional connectivity of this neural subsystem. This 
suggested mechanism is not only consistent with recent human brain imaging data showing 
that subanaesthetic ketamine treatment increases global brain functional connectivity 
(Driesen et al., 2013), but is also consistent with emerging electophysiological data 
supporting a reduced signal-to-noise after ketamine treatment in the hippocampal CA3 
subfield (Saunders et al., 2011) and of gamma oscillations in the somatosensory 
thalamocortical system (Kulikova et al., 2012) of rodents. Our data suggest that similar 
mechanisms may occur in the PFC, where ketamine is known to directly increase the 
amplitude of gamma oscillations through the blockade of local NMDA receptors (McNally et 
al., 2011) and where the NMDA receptor antagonist MK-801 has been shown to disrupt the 
firing pattern of PFC neurons (Jackson et al., 2004). Interestingly, our recent data show that 
prolonged NMDA receptor hypofunction, as induced by repeated subchronic phencyclidine 
treatment in rats, is capable of inducing the functional network dysconnectivity 
characteristic of chronic schizophrenia (Dawson et al., 2012a). This suggests that plasticity 
dependent modifications in brain circuitry that result from prolonged but not acute NMDA 
receptor hypofunction, such as decreased expression of parvalbumin in GABAergic neurones 
(Cochran et al., 2003) and altered neurotransmitter receptor expression (Steward et al., 
2004), are essential in order to recapitulate the alterations in functional brain networks seen 
in chronic schizophrenia. Moreover, sustained NMDA receptor hypofunction induces the 
hypofrontality characteristic of the disorder (Cochran et al., 2003; Dawson et al., 2012a; 
2012b), whereas acute ketamine treatment induces a contrasting hyperfrontality, a paradox 
that is yet to be resolved given the schizophrenia-like symptoms induced by acute ketamine 
treatment. It may be the case that ketamine induced alterations in functional brain network 
structure have the greatest translational relevance to those symptoms present during acute 
psychotic episodes rather than those that remain present in chronic schizophrenia patients 
treated with antipsychotics.  That is to say that ketamine induced alterations in functional 
brain networks may more accurately model the state-dependent alterations in functional 
brain connectivity that are present during an acute psychotic episode, rather than the trait 
alterations in functional brain network connectivity evident in chronic schizophrenia, which 
may be masked during acute psychosis. The suggestion that decreased brain network 
connectivity may be a trait of brain networks in schizophrenia is supported by recent 
evidence showing that individuals with an increased risk for the disorder show altered brain 
network properties characteristic of schizophrenia (Li et al., 2012), again supporting network 
dysconnectivity. However, as the properties of functional brain networks during acute 
psychosis are yet to be characterised, the possibility that state dependent alterations in 
brain network connectivity during acute psychosis may mask those evident as a trait of the 
disorder remains speculative. The characterisation of functional brain network connectivity 
in schizophrenic individuals during their first episode of acute psychosis and subsequently 
when stabilised by antipsychotic treatment would be an essential step in testing this 
hypothesis, and also in further resolving the true translational relevance of subanaethetic 
ketamine treatment. The suggestion that subanaesthetic ketamine treatment may have 
greater translational relevance to at least some of the cognitive deficit seen in the disorder 
that are evident during the early stages of the disease but not in chronic schizophrenia is 
supported by recent data (Hauser et al., 2011; Moore et al., 2013).  
 
Our data also support thalamic hyperconnectivity in the brain networks of animals treated 
with ketamine. This is consistent with our previous observation, that acute ketamine 
treatment enhances connectivity between the thalamic nuclei (Dawson et al., 2013). This 
contrasts with the thalamocortical dysconnectivity widely reported in schizophrenia, which is 
particularly evident in terms of PFC-thalamic dysconnectivity (Marenco et al., 2012; Welsh et 
al., 2010; Zhou et al., 2007; Woodward et al., 2012), although this is not always found 
(Klingner et al., 2013; Schlsser et al., 2003). In addition, there are examples of enhanced 
thalamic connectivity to other cortical subfields in schizophrenia, such as to motor and 
somatosensory areas (Woodward et al., 2012) and to the insular cortex (Corradi-Dell’Acqua 
et al., 2012). Interestingly, we did find evidence for enhanced thalamic connectivity to 
cortical regions (Figure 4C), with the exception of the PFC, following ketamine treatment in 
this study. Our previous data, and data from other groups, suggest that the direct actions of 
ketamine in the reticular thalamus (RT) may be a key mechanism through which ketamine 
promotes the abnormal connectivity of other thalamic regions, in part through the 
disinhibition of thalamocortical projections (Dawson et al., 2013; Zhang et al., 2009). Given 
that the cognitive and functional roles of specific thalamic nuclei and their cortical 
connections is poorly defined, with the exception of the PFC-thalamic connection, the 
potential contribution of these alterations to ketamine’s ability to model schizophrenia 
certainly warrants further systematic investigation. Clearly, our data suggest a disconnect 
between many of the systems level alterations induced by acute ketamine treatment and 
those seen in the brain of schizophrenia patients and thus these must be more clearly 
resolved in order to more rigorously define the specific translational value of this model. 
Understanding the plasticity alterations that occur in the brain as a result of repeated NMDA 
receptor blockade may be particularly important in elucidating the contribution of this 
mechanism to the alterations in brain network connectivity seen in schizophrenia. 
For the first time we have shown that bipartite functional interactions between distinct 
neural subsystems are dramatically altered as a result of acute NMDA receptor blockade. In 
particular the functional connectivity of the PFC, thalamus, hippocampus and 
neuromodulatory neural subsystems are significantly altered by ketamine treatment. The 
ketamine induced alterations we have shown in the bipartite connectivity of these neural 
subsystems, as determined by GSVD analysis, parallel those we have previously reported 
using regional functional connectivity analysis (Dawson et al., 2013), that included a 
ketamine induced enhancement of functional connectivity between selected 
neuromodulatory nuclei (dorsal raphé and locus coeruleus) and the PFC. As the 
neuromodulatory nuclei defined in this study included both the raphé (dorsal [DR] and 
medial [MR]), sources of serotonergic innervation to the PFC, and the locus coeruleus (LC), a 
primary source of noradrenergic innervation to the PFC, the enhanced connectivity between 
these neural subsystems is consistent with the known ability of acute ketamine to 
profoundly enhance both serotonin (Lindefors et al., 1997; Amargos-Bosch et al., 2006) and 
noradrenaline levels in the PFC (Kubota et al., 1999). The altered connectivity of these 
neuromodulatory neurotransmitter systems may directly contribute to the disruption of PFC 
dependent processes by acute NMDA receptor blockade, a suggestion supported by the 
observation that the application of antagonist for the receptors of these neuromodulatory 
systems can attenuate the disruptive effects of NMDA receptor antagonists on PFC 
dependent cognitive processes (Metzer et al., 2011; Mirjana et al., 2004), PFC physiology 
(Jentsch et al., 1988) and other translationally relevant behaviours (Bakshi et al., 1997; 
Stuchlik et al., 2009). Overall, our data suggest that the connectivity of the neuromodulatory 
subsystem to the PFC is profoundly altered by acute ketamine treatment and is likely to 
contributes to ketamine’s disruptive effects on PFC dependent cognitive processes. In 
contrast to the PFC, we found that the bipartite functional connectivity of the thalamus to 
the neuromodulatory subsystem and hippocampus was decreased, whereas thalamic 
connectivity to the cortical subsystems was increased by acute ketamine treatment. The 
direct inhibition of thalamic GABAergic neurons, consistent with the decreased metabolic 
demand of these nuclei (Figure 1, as 2-deoxyglucose imaging largely reflects the metabolic 
demands of localised synapses), by NMDA receptor blockade (Zhang et al., 2009) may 
underlie the functional dysconnectivity of this neural subsystem from that of the 
neuromodulatory nuclei. This in turn would lead to the disinhibition of thalamic 
glutamatergic projections to the cortex and other neural subsystems (Sharp et al., 2001), a 
suggestion consistent with the enhanced bipartite thalamus-cortex connectivity also seen in 
ketamine treated animals. 
 
Overall, our data suggest that the systems level alterations induced by subanaesthetic 
ketamine treatment are distinct from those seen in chronic schizophrenia. These, along with 
other data, suggest that plasticity dependent alterations in brain circuitry that result from 
chronic but not acute NMDA receptor blockade most accurately reflect the systems level 
differences in brain network functioning seen in schizophrenia. Characterising these 
plasticity mechanisms may provide key insight into the transition from the acute psychotic to 
the chronic disease state in schizophrenia, and could provide opportunities for the 
development of novel treatment interventions. In addition, these data provide dramatic new 
insight into the altered brain functioning, and the altered interactions between defined 
neural subsystems, that result from acute NMDA receptor blockade. 
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8. Legends 
8.1 Tables 
 
Table 1. Altered hub brain regions in the functional brain networks of control and 
ketamine-treated mice. Data shown as z-score for each centrality measure (degree, 
betweenness and closeness) for each hub brain region in the brain networks of control and 
ketamine treated animals. Values in bold denote centrality measures in which a given brain 
region reaches the defined criteria (z-score >1.96 relative to 11,000 calibrated random 
Erds-Rényi graphs across the entire correlation threshold range [T = 0.3 to 0.4]) to be 
considered as a hub. **denotes p<0.01 significant difference in a given centrality measure 
between ketamine treated and control animals (determined by comparison of the difference 
in real brain networks to that in 11,000 random permutations of the data across the entire 
correlation threshold range (T = 0.3 to 0.4) with Bonferroni post-hoc correction for multiple 
comparisons). Full data are shown in the supplemental material Tables S2(A-D). 
 
8.2 Figures 
 
Figure 1. Ketamine induced alterations in overt local cerebral glucose utilization (LCGU). 
Data shown as mean ± SEM. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 
significant difference from control (saline treated) animals (t-test). Full data for all brain 
regions analysed are shown in Supplemental Table S1(A-D). 
 
Figure 2. Ketamine induced alterations in global functional brain network topography. 
Acute Ketamine treatment (30 mg.kg-1) resulted in functional brain networks that displayed 
a significantly increased (A) mean degree (P = 0.0490), had a similar (B) average path length 
(P = 0.207) but a significantly increased (C) mean clustering coefficient (P = 0.0333) in 
comparison to networks in control animals. When the functional brain networks of each 
experimental group were compared at the same cost there was no significant difference 
between the two groups in terms of the (D) average path length (P = 0.0987) or mean 
clustering coefficient (P = 0.1448). The significance of ketamine induced alterations in global 
network measures was analyzed by comparison to that in networks generated from 5,000 
(A,B,C) or 1,000 (D,E) random permutations of the raw experimental data. Significance was 
set at p<0.05. 
 
Figure 3. Hub brain regions in the functional brain networks of control and ketamine 
treated mice. Graph representations of the 2-DG brain networks in control and ketamine 
treated mice. Brain networks are shown at the 0.4 correlation threshold (T = 0.4). Solid 
edges between nodes represent a positive correlation in cerebral metabolism between brain 
regions, whereas broken connections (edges) denotes a negative correlation in cerebral 
metabolism between two brain regions. If regional centrality, for any centrality measure, 
surpassed the z > 1.96 threshold, calculated in comparison with 11,000 calibrated random 
Erds-Rényi graphs, across the entire correlation threshold range (T = 0.3 to 0.4), then that 
region was considered to be a hub in the functional brain network. Large nodes are those 
that are defined as important hubs in the network. Node colour denotes the centrality 
measure in which a brain region was considered to be an important hub in the brain 
network. These graphs were generated using Pajek software 
(http://pajek.imfm.si/doku.php?id=download). 
 
Figure 4. Ketamine induced alterations in bipartite neural subsystem interactions.  (A) 
Heatmaps showing the clustering of neural subsystems in control and ketamine treated 
animals brain network matrices following GSVD reordering. Warm colours (red/orange) 
represent high/positive functional correlations between brain regions and cold colours 
(blue/green) represent low/negative correlations between brain regions. The Control 
reordered matrix identified clusters of brain regions present in the control group not present 
in ketamine treated animals, and the ketamine ordered matrix shows clusters present in 
ketamine treated animals not present in controls. (B) Brain region lists showing the order of 
brain regions in the original (alphabetical) and GSVD reordered matrices for ketamine 
treated and control animals. (C) Summary diagram of significant neural subsystem bipartite 
interactions seen in the GSVD reordered matrices of control but not ketamine treated 
animals (defined in blue) and those seen in ketamine treated but not control animals 
(defined in red). Values indicate the significance level of the given bipartite neural subsystem 
interaction, determined by comparison of the joint variance of each bipartite neural 
subsystem in the real GSVD reordered matrices as compared to that seen in 10,000 random 
permutations of the real data. These p-values were adjusted post-hoc by Bonferroni-Holm 
correction for multiple (110) comparisons. Significance is set at p<0.05. Full data are shown 
in the Supplementary Material (Tables S3[A-B]). 
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Thalamus 0.043 0.040 0.011
0.043
0.022
Septum/DB
Basal Ganglia
Multimodal
Hippocampus
Prefrontal
Medial Prefrontal
Cortex
Mesolimbic
Amygdala
Brain Region 
Degree Betweenness Closeness
Control Ketamine Control Ketamine Control Ketamine 
Prefrontal Cortex 
medial Prelimbic Cortex, Layer 3 (mPrL3) 0.02 2.03** -0.63 0.41 -2.09 0.48 
Lateral Orbital Cortex (LO) -1.17 2.61** -0.48 1.04 -3.38 1.87 
Cortex 
Retrosplenial Cortex (RSC) 2.38 -0.53** 0.39 -0.17 1.21 -1.22 
Thalamic Nuclei       
Mediodorsal Thalamus (MDthal) 0.23 3.25** -1.18 1.00 -2.01 3.23 
Anteromedial Thalamus (AMthal) 0.52 2.00 -0.01 -0.11 -0.73 0.95 
Ventromedial Thalamus (VMthal) 1.33 4.50** 0.44 2.67** 0.45 5.22 
Centrolateral Thalamus (CLthal) 0.49 3.45** -1.05 0.99 -1.83 3.57 
Mesolimbic System       
Nucleus Accumbens Core (NacC) 1.37 2.85 0.62 0.16 0.15 2.50 
Nucleus Accumbens Shell (NacS) 2.54 2.99 0.83 1.48 1.21 3.14 
Amygdala       
Medial Amygdala (MeA) -2.79 2.17** -1.90 1.47 -6.75 1.62 
Basolateral Amygdala (BLA) -0.54 1.95** -0.23 0.25 -1.99 1.49 
Septum/Diagonal Band of Broca       
Lateral Septum (LS) -1.94 1.42** -0.58 2.87** -4.15 0.51 
Mutlimodal       
Medial Habenula (mHab) -2.09 2.16** -0.97 0.06 -4.35 0.95 
Mamillary Body (MB) 2.20 -2.37** 1.41 -1.95 0.88 -4.65 
Interpeduncular Nucleus (IP) 3.24 2.35 1.42 0.62 1.43 1.60 
Venterolateral Lemniscus (VLL) 1.67 2.59 -0.64 1.16 -0.57 1.82 
 
